Adjuvant radiotherapy after liver surgery for liver cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This phase II clinical trial investigates the safety and efficacy of adjuvant simultaneously integrated boost (SIB) radiotherapy in patients with hepatocellular carcinoma (HCC) who have undergone narrow-margin hepatectomy. Participants will receive targeted radiotherapy to the high-risk areas of the tumor bed, with specific dosage plans aimed at optimizing treatment while minimizing damage to surrounding healthy tissue. The primary goal is to assess the three-year overall survival rate, while secondary outcomes include disease-free survival, local control rates, and the incidence of toxic events.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Pathological diagnosis of HCC after hepatectomy with narrow pathological margins (\< 1 cm)
* Age \> 18 years
* Recovery from surgery with an Eastern Cooperative Oncology Group performance status score of 0 or 1
* Child-Push Score: A5-A6
* Estimated life expectancy \> 3 months
* No distant metastasis (M0)
* Blood routine examination: Hb≥80g/L, ANC≥1.0x10\^9/L, PLT≥50x10\^9/L
* Hepatic function: alanine transaminase(ALT) and aspartate transaminase(AST) ≤1.5 times ULN; or ALT ≤ULN and AST ≤6 times ULN exclude possibility of heart disease
* Renal function: creatinine(CRE) and blood urea nitrogen(BUN)≤1.5 times ULN
* Voluntary to participate and sign informed consent

Exclusion Criteria:

* History of malignancies, except for basal cell skin carcinoma and in situ carcinoma of the cervix
* Had prior abdominal irradiation
* Had prior liver transplantation
* Had serious myocardial disease or renal failure
* Had moderate or severe ascites with obvious symptoms
* Duration from surgery ≥ 3 months

Where it's running

• Bo Chen
  Beijing, China Recruiting

Study contacts

• Study coordinator: Bo Chen, MD
• Email: chenboo@outlook.com
• Phone: 00861324000876

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• HAIC plus iparomlimab or tuvonralimab with bevacizumab, followed by SBRT for advanced liver cancer with portal vein involvement or limited metastases

  This trial will test whether giving hepatic artery infusion chemotherapy with an immune checkpoint antibody (iparomlimab or tuvonralimab) plus bevacizumab, followed by focused stereotactic radiation, helps people with advanced hepatocellular carcinoma that involves the portal vein or has a small number of metastases.

  Recruiting Phase 2 Shandong Cancer Hospital and Institute · Jinan, Shandong · NCT07062055

• Exploring the link between plasma sphingolipids and radiotherapy effectiveness in liver cancer

  This study is trying to see if the levels of certain fats in the blood can help predict how well radiotherapy works for people with liver cancer.

  Recruiting Nanfang Hospital, Southern Medical University · Guangzhou, Guangdong · NCT06864221

• Moderate-dose radiotherapy combined with Pembrolizumab for liver cancer with blood vessel blockage

  This study is testing if combining a specific type of radiation therapy with the immunotherapy drug Pembrolizumab can help people with liver cancer that has blocked blood vessels feel better and live longer.

  Recruiting Phase 2 Cancer Institute and Hospital, Chinese Academy of Medical Sciences · Beijing, Beijing Municipality · NCT06389422

• Analysis of outcomes and side effects in patients receiving radiation therapy

  This study looks at the results and side effects of radiation therapy in patients at Winterthur Cantonal Hospital to see how treatment can be improved for future patients.

  Recruiting Kantonsspital Winterthur KSW · Winterthur, Canton of Zurich · NCT05192876

• Primary tumor removal with targeted lymph node removal plus radiation for biliary tract cancer with lymph node spread

  This phase II study tests whether removing the main tumor and select nearby lymph nodes, followed by postoperative radiation, helps patients with biliary tract cancer and lymph node metastases.

  Recruiting Phase 2 Cancer Institute and Hospital, Chinese Academy of Medical Sciences · Beijing, Beijing Municipality · NCT07893392

• InstaSure Non-Invasive Finger-Press Test for HCC

  This study tests a non-invasive finger-skin test to help identify hepatocellular carcinoma in adults.

  Recruiting Beijing Municipal Administration of Hospitals · Beijing, Beijing Municipality · NCT07848750

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.